4//SEC Filing
Heyman Richard A. 4
Accession 0001415889-24-025500
CIK 0001672619other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 4:18 PM ET
Size
8.0 KB
Accession
0001415889-24-025500
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Sale
Common Stock
2024-10-18$30.00/sh−817$24,512→ 123,673 total - Sale
Common Stock
2024-10-18$30.00/sh−753$22,592→ 27,165 total(indirect: See footnote)
Holdings
- 37,407(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
- [F4]The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001584759
Filing Metadata
- Form type
- 4
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 4:18 PM ET
- Size
- 8.0 KB